Account
Watchlists
Bookmarks
Pricing
Bearish
5
Neutral
6
Bullish
3
Bearish
25
Neutral
6
Bullish
15
Bearish
20
Neutral
0
Bullish
12
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
350.70 | 1,033 Cr | 9.23 | 2.64 | 0.71 | 28.67 | 27.38 | 17.02 | |
1445.00 | 830 Cr | 40.13 | 2.77 | 0.13 | 6.89 | 8.00 | 4.27 | |
78.60 | 780 Cr | 20.17 | 2.39 | 0.96 | 11.84 | 15.90 | 7.61 | |
483.05 | 458 Cr | 69.23 | 6.31 | 0.00 | 9.12 | 9.87 | 2.79 | |
215.50 | 356 Cr | 35.44 | 3.25 | 0.00 | 8.14 | 13.29 | 5.02 | |
12.88 | 314 Cr | 18.75 | 1.47 | 0.00 | 7.77 | 8.53 | 5.23 | |
55.00 | 206 Cr | — | 0.00 | 0.00 | 46.67 | -53.26 | -14.66 |
Anuh Pharma Limited is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and bulk drugs, prominently serving the antibiotics, erythromycin salts, and chloramphenicol market segments.
Recently, Anuh Pharma has expanded its production capacity by commissioning an additional intermediate block, enhancing its capability to produce APIs and meet growing market demands.
The company reported a 21.14% revenue growth in H1 FY 2025 compared to H1 FY 2024. However, a decline in EBITDA highlights challenges due to reduced high-margin product sales and non-recurring expenses.
A continued focus on mature markets and dedicated R&D efforts in diabetic care and anti-malarial therapies further showcases Anuh Pharma's strategic initiatives to drive future growth.
Anuh Pharma's commitment to clean energy and environmental responsibility is evident with new solar power installations and increased effluent treatment capacity to support sustainable operations.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
780 Cr
Moderate Risk
20.2
59.2
1.3
2.4
121.00
74.03
Sales CAGR
1Y
2.24%
3Y
10.78%
5Y
16.60%
10Y
7.62%
Profit CAGR
1Y
-21.16%
3Y
15.71%
5Y
27.05%
10Y
6.98%
ROE
TTM
11.84%
3Y
16.73%
5Y
16.04%
10Y
15.14%
ROCE
TTM
15.90%
3Y
21.74%
5Y
21.04%
10Y
20.33%
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Performance
STEADY PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
HIGH MARGIN
Technicals
Bearish
Risk
MODERATE RISK
Market Cap
₹ 780 Cr
P/E
20.17
